[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 7 sources · 15 days · First seen · Last updated

Swiss corporate financial performance

Overview

In the second half of 2026, Swiss-based companies reported varying financial results. Helvetia Baloise announced an underlying profit of 631.6 million Swiss francs for the first half of 2026, noting that while IFRS net profit was lower due to a 671.7 million Swiss franc amortization of intangible assets from a merger, the integration process is exceeding synergy targets.

During the same period, HBM Healthcare Investments reported a projected profit of approximately 177 million Swiss francs for its first semester of the 2026/27 fiscal year, an increase from 96 million francs the previous year. This growth was largely driven by private equity holdings and valuation increases in biotech firms.

Entities

Eli Lilly · Helvetia Baloise · Natera · argenx · HBM Healthcare Investments

Timeline

  1. [BUSINESS] 2 sources
    HBM Healthcare reports significant increase in half-year profit

    HBM Healthcare Investments expects a first-semester profit of approximately 177 million Swiss francs, driven largely by strong performance in private equity holdings and biotech acquisitions.

  2. [BUSINESS] 5 sources
    Helvetia Baloise reports 631.6 million CHF underlying profit for H1 2026

    Helvetia Baloise reported 631.6 million CHF in underlying H1 2026 profit, exceeding targets despite a lower IFRS net profit caused by merger-related asset write-downs.

Sources

blog.segurostv.es · cash.ch · finanzen.ch · finanznachrichten.de · finews.com · lfm.ch · moneycab.com